Guatemala vs Norway: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Guatemala
0.0%
in 2024
Norway
0.0%
in 2024
Guatemala rank
143rd
Norway rank
143rd
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Guatemala
- Norway
How they compare
Guatemala currently reports 0.0% against 0.0% in Norway, a difference of 0.0%.
Across all 10 years both countries report, Norway has been ahead every year.
Guatemala ranks 143rd and Norway ranks 143rd of 215 countries.
Head to head by decade
| Decade | Guatemala | Norway | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.1% | 0.1% | 0.0% | — |
| 2020s | 0.0% | 0.0% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Guatemala or Norway?
- Guatemala, at 0.0% against 0.0% in Norway as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Guatemala and Norway?
- 0.0%, with Guatemala ahead.
- How many years of comparable data are there for Guatemala and Norway?
- 10 years are reported by both, from 2015 to 2024.
- How do Guatemala and Norway rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Guatemala ranks 143rd and Norway ranks 143rd of 215 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.